WHAT IS CLAIMED IS:

1. (currently amended) A compound having the formula I:



I

in which:

Ring A is a (C_3-C_8)-cycloalkanediyl ring or a (C_3-C_8)-cycloalkenediyl ring,

R1 and R2 are:

(a) Independently of one another H, F, Cl, Br, CF_3, OCF_3, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, SCF_3, SF_5, OCF_2-CHF_2, (C_6-C_{10})-aryl, (C_6-C_{10})-aryloxy, OH, NO_2; or

(b) together with the phenyl, pyridine, 1H-pyrrole, thiophene or furan ring form fused, partially or unsaturated bicyclic (C_6-C_{10})-aryl, (C_5-C_{11})-heteroaryl;

R3 is:

H, (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl, (C_1-C_3)-alkyl-(C_3-C_8)-cycloalkyl, phenyl, (C_1-C_3)-alkyl-phenyl, (C_5-C_6)-heteroaryl, (C_1-C_3)-alkyl-(C_5-C_6)-heteroaryl, or (C_1-C_3)-alkyl fully or partially substituted by F;

W is:

(a) ~~is~~ CH and o = 1, or

~~(b) is O, S or NR10 if o = 0;~~

X is (C_1-C_6)-alkanediyl, wherein one or more carbon atoms of the (C_1-C_6) alkanediyl may be replaced by oxygen atoms;

Y1 is $(CR13R14)_p$, wherein p is 1 or 2;

Y2 is CH2, O, S, SO, SO_2 or NR9;

n is 0-2;

R4 is H, (C1-C6)-alkyl; F if Y2 is not O; NR9;

R5 is H, $(C_1\text{-}C_6)$-alkyl; F if Y2 is not O; NR9;

R6 is H, $(C_1\text{-}C_6)$-alkyl; or F if n is not 0;

R7 is:

H, F (if n is not 0), $(C_1\text{-}C_6)$-alkoxy, $(C_2\text{-}C_6)$-alkenyl, $(C_2\text{-}C_6)$-alkynyl, $(C_3\text{-}C_8)$-cycloalkyl, $(C_1\text{-}C_6)$-alkyl that may be unsubstituted or substituted by one or more radicals selected from the group consisting of:

hydroxyl, phenyl, $(C_5\text{-}C_{11})$-heteroaryl, $(C_1\text{-}C_6)$-alkoxy and NR11R12, or phenyl that may be unsubstituted or substituted by one or more radicals from the group consisting of hydroxy, $(C_1\text{-}C_6)$-alkoxy, F and CF_3,

with the proviso that R7 is not NR11R12 or $(C_1\text{-}C_6)$-alkoxy if R6 = F;

R6 and R7 are together with the carbon atom that carries them $(C_3\text{-}C_8)$-cycloalkyl;

R8 is H or $(C_1\text{-}C_6)$-alkyl;

R9 is:

H, $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, $(C_2\text{-}C_6)$-alkynyl, aryl-$(C_1\text{-}C_4)$-alkyl, CO-$(C_1\text{-}C_6)$-alkyl, CO-$(C_6\text{-}C_{10})$-aryl, CO-$(C_1\text{-}C_6)$-alkyl-$(C_6\text{-}C_{10})$-aryl, CO-$(C_5\text{-}C_{11})$-heteroaryl, C(O)-O-$(C_1\text{-}C_6)$-alkyl, C(O)-O-$(C_1\text{-}C_6)$-alkyl-$(C_6\text{-}C_{10})$-aryl, C(O)-O-$(C_6\text{-}C_{10})$-aryl, C(O)-O-$(C_5\text{-}C_{11})$-heteroaryl, SO_2-$(C_1\text{-}C_6)$-alkyl, SO_2-$(C_1\text{-}C_6)$-alkyl-$(C_6\text{-}C_{10})$-aryl, SO_2-$(C_1\text{-}C_6)$-alkyl-SO_2-$(C_1\text{-}C_6)$-alkyl, SO_2-$(C_6\text{-}C_{10})$-aryl, SO_2-$(C_5\text{-}C_{11})$-heteroaryl, wherein aryl or heteroaryl, or both may be unsubstituted or substituted by $(C_1\text{-}C_6)$-alkyl, O-$(C_1\text{-}C_6)$-alkyl, F, Cl, CO-$(C_1\text{-}C_6)$-alkyl;

R10 is H, $(C_1\text{-}C_6)$-alkyl or $(C_1\text{-}C_6)$-alkyl-phenyl;

R11 is H, $(C_1\text{-}C_6)$-alkyl or $(C_1\text{-}C_6)$-alkyl-phenyl;

R12 is H, $(C_1\text{-}C_6)$-alkyl or $(C_1\text{-}C_6)$-alkyl-phenyl;

R13 is H or $(C_1\text{-}C_6)$-alkyl; and

R14 is H or $(C_1\text{-}C_6)$-alkyl; or

a physiologically acceptable salt of the compound;
a solvate of the compound; or
a physiologically active derivative of the compound.

2. (original) The compound of claim 1 in which

Ring A is $(C_3\text{-}C_8)$-cycloalkanediyl or $(C_3\text{-}C_8)$-cycloalkenediyl, wherein one carbon atom of the $(C_3\text{-}C_8)$-cycloalkanediyl ring or the $(C_3\text{-}C_8)$ cycloalkenediyl ring may be replaced by an oxygen atom; and

X is $(C_1\text{-}C_6)$-alkanediyl, wherein the C_1 or C_2 carbon atom (to Ring A) may be replaced by an oxygen atom.

3. (original) The compound of claim 1, in which

Ring A is cis-cyclohexane-1,3-diyl;

R1 and R2 are:

independently of one another H, F, CF_3, $(C_1\text{-}C_6)$-alkyl, O-$(C_1\text{-}C_6)$-alkyl, or phenyl; or

together with a phenyl ring of the compound form a naphthyl;

R3 is $(C_1\text{-}C_6)$-alkyl, $(C_3\text{-}C_8)$-cycloalkyl, or phenyl;

W is:

CH if o = 1, or

O or S if o = 0;

X is CH_2-O or CH_2-O-CH_2;

Y1 is CH_2;

Y2 is CH_2, O, S, SO, SO_2 or NR9;

n is 0;

R4 is H;

R5 is H;

R6 is H, $(C_1$-$C_6)$-alkyl, or benzyl;

R7 is H, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_6)$-cycloalkyl, phenyl, or benzyl,

R6 and R7 together with the carbon atom that carries them are $(C_3$-$C_6)$-cycloalkyl;

R8 is H; and

R9 is:

H, or

$(C_1$-$C_6)$-alkyl, which may be unsubstituted or substituted by:

$(C_3$-$C_6)$-cycloalkyl, phenyl, $(C_5$-$C_6)$-heteroaryl; CO-$(C_1$-$C_6)$-alkyl, CO-$(C_1$-$C_6)$-alkyl-phenyl, CO-phenyl, C(O)-O-$(C_1$-$C_6)$-alkyl, CO-NH-phenyl, SO_2-$(C_1$-$C_4)$-alkyl, SO_2-$(C_1$-$C_4)$-alkyl-SO_2-$(C_1$-$C_4)$-alkyl, SO_2-tolyl, or a combination thereof,

wherein the phenyl of the substituent for its part may be substituted by O-$(C_1$-$C_3)$-alkyl;

a physiologically acceptable salt of the compound;

a solvate of the compound; or

a physiologically acceptable derivative of the compound.

4. (original) A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.

5. (original) The pharmaceutical composition of Claim 4, further comprising an active compound for treating and/or preventing a metabolic disorder or a disease associated with the metabolic disorder.

6. (original) The pharmaceutical composition of Claim 4, further comprising an antidiabetic.

7. (original) The pharmaceutical composition of Claim 4, further comprising a lipid modulator.

8. -15. (withdrawn)

16. (original) The compound of Claim 2, in which

Ring A is cis-cyclohexane-1,3-diyl;

R1 and R2 are:

independently of one another H, F, CF_3, $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_6)$-alkyl, or phenyl; or

together with a phenyl ring of the compound form a naphthyl;

R3 is $(C_1$-$C_6)$-alkyl, $(C_3$-$C_8)$-cycloalkyl, or phenyl;

W is:

CH if o = 1, or

O or S if o = 0;

X is CH_2-O or CH_2-O-CH_2;

Y1 is CH_2;

Y2 is CH_2, O, S, SO, SO_2 or NR9;

n is 0;

R4 is H;

R5 is H;

R6 is H, $(C_1$-$C_6)$-alkyl, or benzyl;

R7 is H, $(C_1$-$C_6)$-alkyl, $(C_3$-$C_6)$-cycloalkyl, phenyl, or benzyl,

R6 and R7 together with the carbon atom that carries them are $(C_3$-$C_6)$-cycloalkyl;

R8 is H; and

R9 is:

H, or

$(C_1$-$C_6)$-alkyl, which may be unsubstituted or substituted by:

$(C_3$-$C_6)$-cycloalkyl, phenyl, $(C_5$-$C_6)$-heteroaryl; CO-$(C_1$-$C_6)$-alkyl, CO-$(C_1$-$C_6)$-

alkyl-phenyl, CO-phenyl, C(O)-O-(C_1-C_6)-alkyl, CO-NH-phenyl, SO_2-(C_1-C_4)-alkyl, SO_2-(C_1-C_4)-alkyl-SO_2-(C_1-C_4)-alkyl, SO_2-tolyl, or a combination thereof,

wherein the phenyl of the substituent for its part may be substituted by O-(C_1-C_3)-alkyl;

a physiologically acceptable salt of the compound;

a solvate of the compound; or

a physiologically acceptable derivative of the compound.

17.-23. (withdrawn)

24. (original) A pharmaceutical composition comprising the compound of Claim 2 and a pharmaceutically acceptable carrier.

25. (original) A pharmaceutical composition comprising the compound of Claim 3 and a pharmaceutically acceptable carrier.

26. (original) A pharmaceutical composition comprising the compound of Claim 16 and a pharmaceutically acceptable carrier.

Respectfully submitted,

Craig M. Bell

Craig M. Bell Reg. No. 31,812
Attorney for Applicant
Reg. No. 31,812

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2387
Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV2003/0082 US NP